References
1. Tayal U, Prasad S and Cook SA. Genetics and genomics of dilated
cardiomyopathy and systolic heart failure. Genome Med . 2017;9:20.
2. Thomas T, Nancy, Haase,Wayne et al . Heart disease and stroke
statistics–2006 update: a report from the American Heart Association
Statistics Committee and Stroke Statistics Subcommittee.Circulation . 2006;113:85-151.
3. Halliday BP, Cleland JGF, Goldberger JJ et al . Personalizing
Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The
Past, Present, and Future. Circulation . 2017;136:215-231.
4. Sun WP, Li CL, Guo JC et al . Long-term efficacy of implantable
cardiac resynchronization therapy plus defibrillator for primary
prevention of sudden cardiac death in patients with mild heart failure:
an updated meta-analysis. Heart Fail Rev . 2016;21:447-53.
5. Pathak RK, Sanders P and Deo R. Primary prevention implantable
cardioverter-defibrillator and opportunities for sudden cardiac death
risk assessment in non-ischaemic cardiomyopathy. Eur Heart J .
2018;39:2859-2866.
6. Kolodziejczak M, Andreotti F, Kowalewski M et al . Implantable
Cardioverter-Defibrillators for Primary Prevention in Patients With
Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and
Meta-analysis. Ann Intern Med . 2017;167:103-111.
7. Ponikowski P, Voors AA, Anker SD et al . 2016 ESC Guidelines
for the diagnosis and treatment of acute and chronic heart failure: The
Task Force for the diagnosis and treatment of acute and chronic heart
failure of the European Society of Cardiology (ESC)Developed with the
special contribution of the Heart Failure Association (HFA) of the ESC.Eur Heart J . 2016;37:2129-2200.
8. Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al , Task Force
for the Management of Patients with Ventricular A and the Prevention of
Sudden Cardiac Death of the European Society of C. 2015 ESC Guidelines
for the management of patients with ventricular arrhythmias and the
prevention of sudden cardiac death: The Task Force for the Management of
Patients with Ventricular Arrhythmias and the Prevention of Sudden
Cardiac Death of the European Society of Cardiology (ESC)Endorsed by:
Association for European Paediatric and Congenital Cardiology (AEPC).Europace . 2015;17:1601-87.
9. Bansch D, Antz M, Boczor S et al . Primary prevention of sudden
cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy
Trial (CAT). Circulation . 2002;105:1453-8.
10. Steinberg BA, Al-Khatib SM, Edwards R et al . Outcomes of
implantable cardioverter-defibrillator use in patients with
comorbidities: results from a combined analysis of 4 randomized clinical
trials. JACC Heart Fail . 2014;2:623-9.
11. Kober L, Thune JJ, Nielsen JC et al . Defibrillator
Implantation in Patients with Nonischemic Systolic Heart Failure.N Engl J Med . 2016;375:1221-30.
12. Sticherling BASMSKDBSOC. Application of a mortality risk score in a
general population of patients with an implantable cardioverter
defibrillator (ICD). Heart . 2014;100:487-491.
13. Barsheshet A, Moss AJ, Huang DT et al . Applicability of a
risk score for prediction of the long-term (8-year) benefit of the
implantable cardioverter-defibrillator. J Am Coll Cardiol .
2012;59:2075-9.
14. Investigators TAvIDA. A comparison of antiarrhythmic-drug therapy
with implantable defibrillators in patients resuscitated from near-fatal
ventricular arrhythmias. The Antiarrhythmics versus Implantable
Defibrillators (AVID) Investigators. The New England journal of
medicine . 1997;337:1576-1584.
15. Hjalmarson A GS, Fagerberg B, Wedel H et al. Effects of
controlled-release metoprolol on total mortality, hospitalizations, and
well-being in patients with heart failure: the Metoprolol CR/XL
Randomized Intervention Trial in congestive heart failure (MERIT-HF).
MERIT-HF Study Group. JAMA . 2000;283:1295-1302.
16. Saba S, Atiga WL, Barrington W et al . Selected patients
listed for cardiac transplantation may benefit from defibrillator
implantation regardless of an established indication. The Journal
of Heart and Lung Transplantation . 2003;22:411-418.
17. Ermis C ZG, Zhu AX, Fabian W et al . Improved survival of
cardiac transplantation candidates with implantable cardioverter
defibrillator therapy: role of beta-blocker or amiodarone treatment.J Cardiovasc Electrophysiol . 2003;14:1540-1546.
18. Wells G PR, Healey JS, Talajic M et al . Cardiac
resynchronization therapy: a meta-analysis of randomized controlled
trials. Canadian Medical Association Journal . 2011;183:421-429.
19. Bilchick KC, Kamath S, DiMarco JP et al . Bundle-branch block
morphology and other predictors of outcome after cardiac
resynchronization therapy in Medicare patients. Circulation .
2010;122:2022-30.
20. Sohaib SM, Finegold JA, Nijjer SS et al . Opportunity to
increase life span in narrow QRS cardiac resynchronization therapy
recipients by deactivating ventricular pacing: evidence from randomized
controlled trials. JACC Heart Fail . 2015;3:327-36.